Predicting, preventing, and identifying delirium after cardiac surgery
© O’Neal and Shaw. 2016
Received: 28 October 2015
Accepted: 29 March 2016
Published: 26 April 2016
Delirium after cardiac surgery is a major problem. The exact mechanisms behind delirium are not understood. Potential pathways of delirium include neurotransmitter interference, global cognitive disorder, and neuroinflammation. Several predisposing and precipitating risk factors have been identified for postoperative delirium. The development of delirium following cardiac surgery is associated with worse outcomes in the perioperative period. Multiple interventions are being explored for the prevention and treatment of delirium. Studies investigating the potential roles of biomarkers in delirium as well as pharmacological interventions to reduce the incidence and duration of delirium are necessary to mitigate this negative outcome.
KeywordsPostoperative delirium Cardiac surgery Neuroinflammation
Delirium is a syndrome defined as an acute state of confusion and inattention which may be accompanied by an altered level of consciousness and disorganized thinking (Cole 2004). The American Psychiatric Association’s Diagnostic and Statistical Manual, 5th edition (DSM-V), provides five key components of delirium (Association AP 2013): a disturbance in attention and awareness; the disturbance is acute and develops over a short period of time while fluctuating during the course of the day; a disturbance in cognition occurs; these disturbances are not explained by another neurocognitive disorder and do not occur during a state of reduced level of arousal including coma; and there is evidence to suggest that the disturbance is caused by a medical condition, substance intoxication or withdrawal, or side effect of a medication. Other features of delirium may include psychomotor disturbances and variable emotional states. Delirium can be categorized into three subgroups: hypoactive, hyperactive, or mixed. The most common type of delirium is hypoactive. When making the diagnosis of delirium, agitation must not be misinterpreted as hyperactive delirium.
Given the range of symptoms and sub-types, the diagnosis of delirium may be difficult and under-recognized by healthcare professionals (Boustani et al. 2010). Several scales are available to assist in making the correct diagnosis. A comparison of methods in the intensive care unit (ICU) found the confusion assessment method for the ICU (CAM-ICU) to be the most valid and reliable delirium assessment tool when compared with the Nursing Delirium Screening Scale (Nu-DESC) and Delirium Detection Score (DDS) (Luetz et al. 2010). Using these tests is time-consuming, especially for providers not formally trained to complete the assessment. The optimal method(s) for assessing postoperative delirium following surgery has yet to reach a generalized consensus although the CAM-ICU is the most commonly used method by clinicians.
Postoperative delirium has been studied in various surgical patient populations. The most extensively studied groups are patients undergoing orthopedic procedures such as total hip arthroplasty or total knee arthroplasty and cardiovascular surgery patients (van Meenen et al. 2014). Delirium is associated with negative hospital outcomes including a tenfold increased risk of death, a fivefold increased risk of nosocomial complications (Inouye 2006), poor 1-year functional recovery, and postoperative cognitive decline (Saczynski et al. 2012). The long-term cognitive decline seen in some patients after the development of delirium is similar to that of Alzheimer’s patients (Pandharipande et al. 2013). With reports of up to 50 % of patients over 60 years old developing postoperative delirium following cardiac surgery (Rudolph et al. 2009), this patient population poses a major burden for healthcare.
This review article discusses the pathophysiology, risk factors, and complications of postoperative delirium following cardiac surgery. Pharmacological interventions which may reduce postoperative delirium and the potential role of biomarkers in this patient population are presented. In addition, we discuss several considerations for future studies in the field.
Neurotransmitter interference may lead to delirium. Reduced levels of plasma cholinesterase activity have a correlation with delirium (Cerejeira et al. 2012; Trzepacz 1996), while increased levels of dopamine may also play a part (Gaudreau & Gagnon 2005). This theory is further supported by evidence which suggests anticholinergic medications and dopaminergic medications instigate delirium (Gaudreau & Gagnon 2005; Trzepacz & van der Mast 2002).
Other theories focus on a more global cognitive disorder in which a single molecule cannot be implicated in delirium, but rather communication in the brain as a whole is impaired. This may include disturbances in the prefrontal and parietal networks, or subcortical structures including the basal ganglia, reticular activating system, thalamic nuclei, and cerebellum (Trzepacz & van der Mast 2002).
In cardiac surgery, the exposure to CPB and the stress endured by the patient produces significant inflammation, and the processes of neuroinflammation provide a logical pathway. This may also hold true in various ICU patients with a diagnosis of sepsis, severe burn injury, or polytrauma. Yet the evidence for an imbalance of certain neurotransmitters and delirium is supported and has been known for years (Cerejeira et al. 2012; Trzepacz 1996). Therefore, delirium is likely multifactorial in nature and components from each theory may be involved.
A direction to expand our understanding of the mechanisms behind delirium and to identify patients at increased risk for delirium after cardiac surgery is through targeting biomarkers. Several studies have investigated biomarkers in heart disease, dementia, heart failure, and various settings of delirium, mostly in critically ill patients (Wiltfang 2014; Gaggin & Januzzi 2013; van den Boogaard et al. 2011; Khan et al. 2011). Multiple biomarkers have associations with delirium and may offer support when assessing risk, establishing diagnosis, and quantifying severity of delirium (Khan et al. 2011; Marcantonio et al. 2006).
A focused approach when evaluating biomarkers is necessary, and one that aims to quantify the probable components of neuroinflammation—endothelial dysfunction, BBB compromise, and neuronal injury—as they relate to cardiac surgery and postoperative delirium may be a promising direction. Previous studies have included pro-inflammatory, anti-inflammatory, and also neuron-specific biomarkers. A study investigating both IL-2 and TNF-α in coronary artery bypass grafting (CABG) patients with CPB not only found a correlation between each biomarker and delirium but also provided cutoff levels for increased risk of 907.5 U/ml and 10.95 pg/ml, respectively (Kazmierski et al. 2014). High levels of IL-2 were associated with a higher risk of delirium following cardiac surgery in another study (Baranyi & Rothenhausler 2014). A prospective cohort looking at pterins in postoperative delirium found that the preoperative neopterin level predicted delirium and postoperative neopterin and homovanillic acid levels were associated with delirium after cardiac surgery (Osse et al. 2012). Even with several studies showing associations of specific biomarkers and delirium, a review concluded that not enough evidence existed to support the clinical use of any biomarker for the diagnosis of delirium (Khan et al. 2011). The review did however state that S100B, insulin-like growth factor-1 (IGF-1), and some inflammatory markers demonstrated promising results.
The biomarker S100B has been associated with delirium and acute brain dysfunction in previous studies and is considered a validated measure of BBB disruption (Blyth et al. 2009). BBB disruption and neuron injury via neuroinflammation may contribute to delirium, and therefore, S100B provides support for this theory. Ubiquitin C-terminal hydrolase L1 (UCHL1) is a neuron-specific enzyme recognized in traumatic brain injury patients as a marker for direct neuron injury (Blyth et al. 2011; Brophy et al. 2011). In addition, a link between this enzyme and neurodegeneration has been suggested (Figueiredo-Pereira et al. 2014; Jara et al. 2013). The biomarker UCHL1 has yet to be investigated in delirium and could provide a novel way to predict and screen patients at risk for delirium following cardiac surgery by directly detecting injury to neurons. Another pathway to consider is impaired endothelial vascular reactivity as an association with endothelial vascular injury and brain dysfunction has been demonstrated (Hughes et al. 2013).
Many risk factors are associated with postoperative delirium. While some may predispose patients to delirium, other risk factors precipitate delirium such as medications given during the perioperative period. Predisposing risk factors are typically long-standing with the patient and should be recognized preoperatively in order to screen patients for increased risk. Precipitating risk factors must be considered by clinicians when treating any patient, especially patients already at high risk for postoperative delirium. Each type of risk factor can be modifiable or non-modifiable, and if possible, those that are modifiable should be optimized in the perioperative period.
Advanced age is a well-recognized risk factor for postoperative delirium. Age has been shown to be an independent risk factor in numerous studies (Chung et al. 2015; Trabold & Metterlein 2014). And with the average age of patients undergoing open-heart surgery in the mid-1960s (O'Neal et al. 2013), many patients automatically fall into a higher risk stratification.
Patients with cognitive impairment are also at risk for postoperative delirium. The incidence of dementia is estimated at 9.8 per 1000 person-years (Ruitenberg et al. 2001), and with humans living longer in a world of steadily increasing population, the prevalence of dementia will continue to rise over the foreseeable future. Impaired cognition may be unrecognized in some patients as people suffering from mild cognitive impairment may present for surgery undiagnosed as symptoms can be subtle at this stage of the disease (Robinson et al. 2012). Thus, these patients are at a greater risk for delirium without healthcare workers being aware. Clinicians should consider screening patients for cognitive impairment prior to surgery and then attempt to avoid and/or mitigate any potential precipitating risk factors in this population.
Other preoperative conditions found to have associations with postoperative delirium include anemia, dehydration, electrolyte abnormalities, and signs of malnutrition (Trabold & Metterlein 2014). A small prospective study of hospitalized patients over the age of 70 years found anemia and dehydration to be risk factors for delirium (Joosten et al. 2006). The finding of anemia as a risk factor was also demonstrated in patients after lumbar spine surgery (Fineberg et al. 2013). This finding has not been reproduced after cardiac surgery; however, whether or not addressing these risk factors prior to surgery can influence the outcome of delirium has yet to be elucidated. Studies which investigate the incidence of delirium after the correction of anemia, dehydration, or other conditions prior to undergoing cardiac surgery should be conducted.
Another consideration is pharmacotherapy before, during, and after surgery. A review of medications taken by patients in the perioperative period of cardiac surgery identified preoperative antipsychotics as an independent risk factor for delirium (Tse et al. 2012). Other preoperative medications that may contribute to delirium include statins, antihypertensives, anticholinergics, antidepressants, benzodiazepines, and opioids which are common home medications for patients undergoing cardiac surgery (Tse et al. 2012). Intraoperative medications associated with delirium include both fentanyl and ketamine while diazepam has inconclusive results (Tse et al. 2012). As for postoperative medications, risperidone was shown to reduce the incidence of delirium by almost one third when taken by patients after cardiac surgery as a preventive strategy (Prakanrattana & Prapaitrakool 2007). However, the large effect size in reducing delirium in patients receiving risperidone (11.1 vs. 31.7 %; RR, 0.35 (95 % CI 0.16 to 0.77); P = 0.009) has yet to be reproduced.
Oxygen delivery to the brain is critical for optimal performance of the brain’s activities. Cerebral oximetry continuously measures cerebral oxygenation in both hemispheres of the brain and is sometimes used in cardiac surgery as a monitor to stratify risk in patients throughout the perioperative period (Vretzakis et al. 2014). Previous studies have found a correlation between low preoperative cerebral oxygenation and postoperative delirium (Schoen et al. 2011). Desaturations in cerebral oximetry readings while on bypass are associated with several adverse outcomes (Vohra et al. 2009), but whether or not this may contribute to delirium is unknown.
Delirium is a condition that may affect a patient for several days or weeks. It is associated with many significant adverse effects and poor outcomes. The progression of dementia after suffering from an episode of delirium may lead to a significant decline in both physical and cognitive functioning (Morandi et al. 2014). This is also evident in patients without an underlying dementia as delirium is associated with declines in both condition and functional level in older patients (Inouye 2006). After cardiac surgery, patients diagnosed with delirium have a higher risk for falls, increased length of stay in the hospital, higher likelihood of discharge to a nursing home or home with assisted care, and prolonged inpatient physical therapy duration (Mangusan et al. 2015). Delirium after CABG surgery is also associated with increased mortality up to 10 years postoperatively (Gottesman et al. 2010).
The outcomes for patients developing delirium are clearly worse than patients who do not. Whether the poor outcomes are a direct effect of delirium or a marker of disease severity is unclear. Either way, these negative outcomes lead to increased costs in not only the healthcare field but also social costs as families incur the increased burdens of time and money to care for relatives diagnosed with delirium. Strategies to reduce healthcare costs are becoming a major focus within the field of medicine. Interventions to effectively treat delirium and its complications are being explored, and strategies to reduce healthcare costs are on the rise (Zaubler et al. 2013). The treatment of delirium is important, but discovering ways to prevent delirium is ideal and would likely equate to the greatest decrease in overall healthcare costs and improved outcomes.
The identification and correction of risk factors including dehydration, electrolyte imbalance, and anemia are important and should be emphasized in every patient. And while these non-pharmacological interventions and others such as reorientation, effective communication, and maintenance of consistent sleep-wake cycles are considered first-line interventions for delirium (Young et al. 2010), the discovery of pharmacological agents which decrease the incidence or duration of delirium has great potential. With the current lack of understanding behind the exact pathophysiology of delirium, the present prevention and treatment strategies are inadequate. As previously mentioned, second-generation antipsychotics were shown to decrease the incidence of postoperative delirium when administered prophylactically (Hirota & Kishi 2013); however, only one study in this review was specific to cardiac surgery patients (Prakanrattana & Prapaitrakool 2007). Also, a total of six studies were included in this meta-analysis. Other studies have suggested patients taking preoperative antipsychotics are actually at a greater risk for delirium (Tse et al. 2012). The use of antipsychotics is a potential treatment option as they may alter and subsequently correct neurotransmitter imbalances in delirious patients (Hirota & Kishi 2013; Schotte et al. 1996), but the majority of interventions for delirium after cardiac surgery aim to optimize analgesia and sedation regimens in the ICU and preemptively treat delirium.
Postoperative pain may contribute to the condition of delirium (Fong et al. 2006). Pain after cardiac surgery can be moderate to severe with incisions to the lower extremities and sternum and also the placement of chest tubes. With the potential for bleeding and increased risk of kidney injury, nonsteroidal anti-inflammatory drugs (NSAIDs) are not ideal in this patient population. Ketamine is one option for pain postoperatively, but it may increase the risk of delirium (Tse et al. 2012), and the potential side effect of hallucinations should also be considered. The usual analgesic regimen after cardiac surgery includes an opiate. Opiates, such as morphine and hydromorphone, have many deleterious side effects including nausea/vomiting, ileus, bladder dysfunction, and respiratory depression (Memis et al. 2010). Opioids also increase the risk of postoperative delirium, especially in elderly patients (Tse et al. 2012). The use of intravenous acetaminophen (IVA) has been shown in multiple studies to reduce the amount of opiates consumed by surgical patients (O'Neal 2013). IVA possesses no psychoactive properties, and it has both rapid and effective analgesic properties while considered to be a safe and well-tolerated medication (Candiotti et al. 2010). Given the reduction in opiate consumption, reliable analgesic properties, and safety profile, IVA may be an alternative for patients undergoing cardiac surgery.
In addition to optimizing pain control after cardiac surgery, choosing the most appropriate sedation regimen is important when trying to reduce the chance for postoperative delirium. The importance of periodically weaning sedation should not be overlooked. Overly sedating patients is associated with delayed extubation and higher mortality in the ICU (Shehabi et al. 2013; Shehabi et al. 2012). Finding the appropriate balance of sedation and adequate analgesia should be targeted in cardiac surgery patients.
An ideal choice for sedation in the ICU is a medication that provides both sedation and pain relief. Dexmedetomidine is a selective α-2 receptor agonist which provides sedation and also has an analgesic component. Some clinicians use caution before administering this medication given the side effect profile which includes bradycardia, hypotension, and hypertension with loading doses. Cardiac surgery patients have the advantage of pacer wire implants to avoid the side effect of bradycardia, and since these patients are in the ICU, hypotension can be treated with vasopressors when appropriate. A study comparing sedation with propofol to dexmedetomidine in the ICU found no difference between the two with regard to bradycardia and hypotension; however, dexmedetomidine was associated with an increased risk of hypertension in patients receiving a loading dose initially (Xia et al. 2013). This undesired side effect might be avoided by foregoing the loading dose. Given its sedative and analgesic properties with limited side effects, dexmedetomidine could be the ideal medication for cardiac surgery patients, and multiple studies have investigated the role of dexmedetomidine in reducing delirium.
A typical sedation regimen in the ICU includes benzodiazepines and/or propofol. The link between benzodiazepines and delirium has been demonstrated (Zaal et al. 2015; Taipale et al. 2012), and therefore, many trials have aimed to compare these agents to dexmedetomidine. The MENDS trial was a double-blind randomized, controlled trial that found the use of dexmedetomidine to result in fewer days of delirium in medical and surgical ICU patients when compared to lorazepam (Pandharipande et al. 2007). Achieving the goal sedation level was also superior in the dexmedetomidine group, but mortality and cost did not differ when compared to the lorazepam group. A larger randomized, controlled trial SEDCOM suggested that medical and surgical ICU patients sedated with dexmedetomidine spent less time on the ventilator, experienced fewer episodes of delirium, and developed less tachycardia and hypertension than patients sedated with midazolam (Riker et al. 2009). Researchers have used these findings in medical and surgical ICUs to study the effects of dexmedetomidine specifically in cardiac surgery ICU patients.
A meta-analysis including 11 randomized, controlled or cohort studies found the use of dexmedetomidine for sedation in cardiac surgery patients’ shortened ventilator time, reduced the incidence of postoperative arrhythmias, and reduced the incidence of delirium (Lin et al. 2012). An issue with this analysis is that some of the main studies included in the analysis had poor designs and variable methods to assess for delirium. The DEXCOM study was a randomized, controlled trial which showed a decreased duration of delirium (5 vs. 2 days, (95 % CI 1.09 to 6.67); P = 0.0317) in patients sedated with dexmedetomidine versus morphine (Shehabi et al. 2009). The study found no difference in incidence of delirium, although the baseline delirium rate was only 15 %. Propofol was used in both study groups, and when assessing delirium, the CAM-ICU scale was used on both intubated and extubated patients. A prospective, randomized, open-label trial comparing dexmedetomidine to propofol to midazolam for sedation after cardiac surgery found an incidence of only 3 % in the dexmedetomidine group versus 50 % in both the propofol and midazolam groups (Maldonado et al. 2009). The large reduction in incidence of delirium is unprecedented as no other study has shown such a drastic reduction. A retrospective cohort consisting of data collected from 250 hospitals found that patients receiving dexmedetomidine/propofol/midazolam had a decreased incidence of delirium compared to the propofol/midazolam group, but the method for assessing delirium was not described (Dasta et al. 2006). Also, the primary endpoint of this study was cost, which was also reduced in the dexmedetomidine/propofol/midazolam group.
More recent studies continue to support the use of dexmedetomidine after cardiac surgery for reduction of delirium. When comparing dexmedetomidine to remifentanil for sedation after cardiac surgery, a reduction in the incidence of delirium was shown in the dexmedetomidine group (8.96 vs. 22.67 %; P < 0.05) (Park et al. 2014). The study found no differences between the two groups with respect to length of stay in the ICU, time to extubation, hospital length of stay, and other postoperative complications. Another recent single-blinded, prospective randomized trial found that when compared to propofol, the use of dexmedetomidine for sedation after cardiac surgery resulted in reduced incidence (odds ratio (OR) 0.46 (95 % CI 0.23 to 0.92); P = 0.028), delayed onset, and also shorter duration of delirium (Djaiani et al. 2015). A retrospective cohort investigating outcomes after CABG found a decreased mortality in patients receiving dexmedetomidine perioperatively (Ji et al. 2014). A reduction in the risk of delirium in patients receiving dexmedetomidine (adjusted OR, 0.431 (95 % CI 0.265 to 0.701); P = 0.0007) was also reported when compared to patients who did not receive dexmedetomidine. A larger retrospective study including CABG and CABG plus valve surgery patients also found a reduction in delirium (5.46 vs. 7.42 %; adjusted OR, 0.53 (95 % CI 0.37 to 0.75); P = 0.003) and decreased 1-year mortality (3.17 vs. 7.95 %; adjusted OR, 0.47 (95 % CI 0.312 to 0.701); P = 0.0002) in patients receiving dexmedetomidine (Ji et al. 2013).
Other interventions are also being studied. The use of high-dose dexamethasone (1 mg/kg) in cardiac surgery patients failed to show a difference in the incidence or duration of delirium (Sauer et al. 2014). The theory that the inflammatory response from surgery and cardiopulmonary bypass contributes to delirium drove the hypothesis of this study. The use of intraoperative Bispectral Index (BIS)-guided and end-tidal anesthetic concentration-guided depth of anesthesia protocols is another direction investigators have taken (Whitlock et al. 2014). No difference was shown with either of these monitors; however, low average volatile anesthetic dose was found to be a predictor of delirium. This may be reflective of patients with poorer health and could potentially assist with screening for patients at higher risk for delirium.
A systematic review and meta-analysis supported the use of dexmedetomidine, antipsychotics, and multicomponent interventions for strategies to reduce postoperative delirium based on the review of 38 randomized controlled trials but did state that one of the greatest obstacles in evaluating delirium studies is the lack of continuity in evaluation of delirium (Zhang et al. 2013). This is a major issue when clinicians are trying to extrapolate these findings and utilize them in clinical practice. When the majority of the randomized clinical trials on postoperative delirium show vast inconsistencies in the method chosen to evaluate delirium, the evidence may seem insufficient and unreliable by intensivists. And even though evidence suggests benefits of using certain interventions to reduce postoperative delirium after cardiac surgery, more studies are necessary which aim to universalize the assessment of delirium.
Studies on this topic are not lacking in quantity but more so in quality. Establishing a reliable, convenient, and consistent method for diagnosing delirium is a must for researchers in this field. More recent studies utilize multiple assessment tools, but until a universal screening method for delirium is accepted, it will be difficult for studies to change clinical practice with their results.
Projects involving biomarkers and their role in delirium after cardiac surgery are limitless. Aiming to target biomarkers shown to have a correlation with delirium in non-cardiac surgery patients should be investigated in cardiac surgery. Biomarkers linked to the mechanisms of delirium should also be characterized potentially through targeting biomarkers of the neuroinflammatory pathway of endothelial dysfunction, BBB disruption, and neuronal injury. This may lead to identifying patients at higher risk, preemptively treating those patients, and further defining the severity of disease in patients with delirium. Finding ways to effectively treat cerebral oxygen desaturations during CPB may also reduce postoperative delirium.
Modifications to medications administered before, during, and after surgery should continue to be investigated. The avoidance of medications such as benzodiazepines and opiates by using other sedatives and analgesics has proven to decrease delirium. Considering the flaws in studies using dexmedetomidine in the ICU, more research is necessary with this medication to determine the optimal dosing and timing of its use and solidify the evidence that it decreases delirium after cardiac surgery. The use of IVA may limit opiate consumption and play a role in decreasing delirium in these patients. An ongoing trial investigating the effects of both dexmedetomidine and IVA on delirium following cardiac surgery may provide sufficient evidence to support the use of these medications in the prevention of postoperative delirium (NCT02546765). Other analgesics such as gabapentin and pregabalin given preoperatively should also be considered.
Delirium is an ongoing issue in cardiac surgery patients. Many risk factors are known, and some can be modified perioperatively. The complications associated with postoperative delirium lead to increased morbidity and mortality as well as higher healthcare costs. Several interventions in the ICU after cardiac surgery have been investigated, but the results have yet to significantly change clinical practice. The role of biomarkers in postoperative delirium after cardiac surgery is promising but not yet fully elucidated. More research and randomized clinical trials in this field is both warranted and necessary given the negative outcomes associated with delirium.
blood brain barrier
coronary artery bypass grafting
confusion assessment method for the ICU
Delirium Detection Score
Diagnostic and Statistical Manual, 5th edition
intensive care unit
insulin-like growth factor-1
Mini-Mental State Examination
nonsteroidal anti-inflammatory drugs
Nursing Delirium Screening Scale
ubiquitin C-terminal hydrolase L1
The research reported in this publication was supported by the National Institutes of Health under award number 5T32 GM108554. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: Elsevier Inc.; 2013.
- Baranyi A, Rothenhausler HB. The impact of soluble interleukin-2 receptor as a biomarker of delirium. Psychosomatics. 2014;55(1):51–60.View ArticlePubMedGoogle Scholar
- Blyth BJ et al. Validation of serum markers for blood–brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009;26(9):1497–507.View ArticlePubMedPubMed CentralGoogle Scholar
- Blyth BJ et al. Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood–brain barrier function after traumatic brain injury. J Neurotrauma. 2011;28(12):2453–62.View ArticlePubMedGoogle Scholar
- Boustani M et al. Impact and recognition of cognitive impairment among hospitalized elders. J Hosp Med. 2010;5(2):69–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Brophy GM et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma. 2011;28(6):861–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Candiotti KA et al. Safety of multiple-dose intravenous acetaminophen in adult inpatients. Pain Med. 2010;11(12):1841–8.View ArticlePubMedGoogle Scholar
- Cerejeira J et al. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119(6):737–54.View ArticlePubMedGoogle Scholar
- Cerejeira J et al. The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc. 2012;60(4):669–75.View ArticlePubMedGoogle Scholar
- Chung KS et al. Risk factors of delirium in patients undergoing total knee arthroplasty. Arch Gerontol Geriatr. 2015;60(3):443–7.View ArticlePubMedGoogle Scholar
- Cole MG. Delirium in elderly patients. Am J Geriatr Psychiatry. 2004;12(1):7–21.View ArticlePubMedGoogle Scholar
- Dasta JF et al. Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis. Pharmacotherapy. 2006;26(6):798–805.View ArticlePubMedGoogle Scholar
- Djaiani G, et al. Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: a randomized controlled trial. Anesthesiology, 2015.
- Figueiredo-Pereira ME et al. Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci. 2014;7:104.PubMedPubMed CentralGoogle Scholar
- Fineberg SJ et al. Incidence and risk factors for postoperative delirium after lumbar spine surgery. Spine (Phila Pa 1976). 2013;38(20):1790–6.View ArticleGoogle Scholar
- Fong HK, Sands LP, Leung JM. The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg. 2006;102(4):1255–66.View ArticlePubMedGoogle Scholar
- Gaggin HK, Januzzi Jr JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442–50.View ArticlePubMedGoogle Scholar
- Gaudreau JD, Gagnon P. Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. Med Hypotheses. 2005;64(3):471–5.View ArticlePubMedGoogle Scholar
- Gottesman RF et al. Delirium after coronary artery bypass graft surgery and late mortality. Ann Neurol. 2010;67(3):338–44.PubMedPubMed CentralGoogle Scholar
- Hirota T, Kishi T. Prophylactic antipsychotic use for postoperative delirium: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(12):e1136–44.View ArticlePubMedGoogle Scholar
- Hughes CG et al. Association between endothelial dysfunction and acute brain dysfunction during critical illness. Anesthesiology. 2013;118(3):631–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Inouye SK. Delirium in older persons. N Engl J Med. 2006;354(11):1157–65.View ArticlePubMedGoogle Scholar
- Jara JH, Frank DD, Ozdinler PH. Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1. Cell Biochem Biophys. 2013;67(1):45–53.View ArticlePubMedGoogle Scholar
- Ji F et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation. 2013;127(15):1576–84.View ArticlePubMedPubMed CentralGoogle Scholar
- Ji F et al. Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2014;28(2):267–73.View ArticlePubMedGoogle Scholar
- Joosten E et al. Is anaemia a risk factor for delirium in an acute geriatric population? Gerontology. 2006;52(6):382–5.View ArticlePubMedGoogle Scholar
- Kazmierski J et al. Raised IL-2 and TNF-alpha concentrations are associated with postoperative delirium in patients undergoing coronary-artery bypass graft surgery. Int Psychogeriatr. 2014;26(5):845–55.View ArticlePubMedGoogle Scholar
- Khan BA et al. Biomarkers for delirium—a review. J Am Geriatr Soc. 2011;59 Suppl 2:S256–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin YY et al. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? A meta-analysis. Crit Care. 2012;16(5):R169.View ArticlePubMedPubMed CentralGoogle Scholar
- Luetz A et al. Different assessment tools for intensive care unit delirium: which score to use? Crit Care Med. 2010;38(2):409–18.View ArticlePubMedGoogle Scholar
- Maldonado JR et al. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics. 2009;50(3):206–17.View ArticlePubMedGoogle Scholar
- Mangusan RF et al. Outcomes associated with postoperative delirium after cardiac surgery. Am J Crit Care. 2015;24(2):156–63.View ArticlePubMedGoogle Scholar
- Marcantonio ER et al. Serum biomarkers for delirium. J Gerontol A Biol Sci Med Sci. 2006;61(12):1281–6.View ArticlePubMedGoogle Scholar
- Memis D et al. Intravenous paracetamol reduced the use of opioids, extubation time, and opioid-related adverse effects after major surgery in intensive care unit. J Crit Care. 2010;25(3):458–62.View ArticlePubMedGoogle Scholar
- Morandi A et al. Delirium superimposed on dementia strongly predicts worse outcomes in older rehabilitation inpatients. J Am Med Dir Assoc. 2014;15(5):349–54.View ArticlePubMedPubMed CentralGoogle Scholar
- O'Neal JB. The utility of intravenous acetaminophen in the perioperative period. Front Public Health. 2013;1:25.PubMedPubMed CentralGoogle Scholar
- O'Neal WT et al. Preoperative atrial fibrillation and long-term survival after open heart surgery in a rural tertiary heart institute. Heart Lung. 2013;42(6):442–7.View ArticlePubMedGoogle Scholar
- Osse RJ et al. High preoperative plasma neopterin predicts delirium after cardiac surgery in older adults. J Am Geriatr Soc. 2012;60(4):661–8.View ArticlePubMedGoogle Scholar
- Pandharipande PP et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–53.View ArticlePubMedGoogle Scholar
- Pandharipande PP et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Park JB et al. Efficacy and safety of dexmedetomidine for postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg. 2014;47(3):249–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Prakanrattana U, Prapaitrakool S. Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care. 2007;35(5):714–9.PubMedGoogle Scholar
- Riker RR et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489–99.View ArticlePubMedGoogle Scholar
- Robinson TN et al. Preoperative cognitive dysfunction is related to adverse postoperative outcomes in the elderly. J Am Coll Surg. 2012;215(1):12–7. discussion 17–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Rudolph JL et al. Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Sci Med Sci. 2008;63(2):184–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Rudolph JL et al. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation. 2009;119(2):229–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Ruitenberg A et al. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22(4):575–80.View ArticlePubMedGoogle Scholar
- Saczynski JS et al. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012;367(1):30–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Sauer AM et al. Intraoperative dexamethasone and delirium after cardiac surgery: a randomized clinical trial. Anesth Analg. 2014;119(5):1046–52.View ArticlePubMedGoogle Scholar
- Schoen J et al. Preoperative regional cerebral oxygen saturation is a predictor of postoperative delirium in on-pump cardiac surgery patients: a prospective observational trial. Crit Care. 2011;15(5):R218.View ArticlePubMedPubMed CentralGoogle Scholar
- Schotte A et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1–2):57–73.View ArticleGoogle Scholar
- Shehabi Y et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM study). Anesthesiology. 2009;111(5):1075–84.View ArticlePubMedGoogle Scholar
- Shehabi Y et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012;186(8):724–31.View ArticlePubMedGoogle Scholar
- Shehabi Y et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. Intensive Care Med. 2013;39(5):910–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Taipale PG et al. The association between nurse-administered midazolam following cardiac surgery and incident delirium: an observational study. Int J Nurs Stud. 2012;49(9):1064–73.View ArticlePubMedGoogle Scholar
- Trabold B, Metterlein T. Postoperative delirium: risk factors, prevention, and treatment. J Cardiothorac Vasc Anesth. 2014;28(5):1352–60.View ArticlePubMedGoogle Scholar
- Trzepacz PT. Anticholinergic model for delirium. Semin Clin Neuropsychiatry. 1996;1(4):294–303.PubMedGoogle Scholar
- Trzepacz PT, van der Mast R. The neuropathophysiology of delirium. Oxford: Oxford University Press; 2002.Google Scholar
- Tse L et al. Pharmacological risk factors for delirium after cardiac surgery: a review. Curr Neuropharmacol. 2012;10(3):181–96.View ArticlePubMedPubMed CentralGoogle Scholar
- van den Boogaard M et al. Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. Crit Care. 2011;15(6):R297.View ArticlePubMedPubMed CentralGoogle Scholar
- van Meenen LC et al. Risk prediction models for postoperative delirium: a systematic review and meta-analysis. J Am Geriatr Soc. 2014;62(12):2383–90.View ArticlePubMedGoogle Scholar
- Vohra HA, Modi A, Ohri SK. Does use of intra-operative cerebral regional oxygen saturation monitoring during cardiac surgery lead to improved clinical outcomes? Interact Cardiovasc Thorac Surg. 2009;9(2):318–22.View ArticlePubMedGoogle Scholar
- Vretzakis G et al. Cerebral oximetry in cardiac anesthesia. J Thorac Dis. 2014;6 Suppl 1:S60–9.PubMedPubMed CentralGoogle Scholar
- Whitlock EL et al. Postoperative delirium in a substudy of cardiothoracic surgical patients in the BAG-RECALL clinical trial. Anesth Analg. 2014;118(4):809–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Wiltfang J. Clinically validated molecular biomarkers of neurodegenerative dementia. Nervenarzt. 2014;85(11):1372–81.View ArticlePubMedGoogle Scholar
- Xia ZQ et al. Clinical benefits of dexmedetomidine versus propofol in adult intensive care unit patients: a meta-analysis of randomized clinical trials. J Surg Res. 2013;185(2):833–43.View ArticlePubMedGoogle Scholar
- Young J et al. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ. 2010;341:c3704.View ArticlePubMedGoogle Scholar
- Zaal IJ et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015;41(12):2130–7.View ArticlePubMedGoogle Scholar
- Zaubler TS et al. Quality improvement and cost savings with multicomponent delirium interventions: replication of the Hospital Elder Life Program in a community hospital. Psychosomatics. 2013;54(3):219–26.View ArticlePubMedGoogle Scholar
- Zhang H et al. Strategies for prevention of postoperative delirium: a systematic review and meta-analysis of randomized trials. Crit Care. 2013;17(2):R47.View ArticlePubMedPubMed CentralGoogle Scholar